United States — Food and Drug Administration & Savara

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a refusal to file letter for Savara's MOLBREEVI BLA, citing insufficient information, which triggered the stock price drop and subsequent lawsuit.

Savara: Savara is the target of a class action lawsuit due to alleged misrepresentations regarding its MOLBREEVI Biologics License Application, which led to a significant drop in its stock price.

United States — Food and Drug Administration: The United States — Food and Drug Administration's potential non-approval of Savara Inc.'s MOLBREEVI BLA is a key factor in the alleged securities fraud.

Savara: Savara Inc. is the target of a class action securities lawsuit due to alleged false statements and concealment regarding its MOLBREEVI BLA, leading to investor losses.

United States — Food and Drug Administration: The United States — Food and Drug Administration's potential non-approval of Savara's MOLBREEVI BLA is a key allegation in the lawsuit, indicating a regulatory hurdle for the drug.

Savara: Savara is facing a class action lawsuit for allegedly issuing materially false and/or misleading statements regarding its drug MOLBREEVI BLA, which could lead to financial losses for the company and its shareholders.